Start Date
November 30, 2020
Primary Completion Date
November 30, 2021
Study Completion Date
November 30, 2021
Dextenza 0.4Mg Ophthalmic Insert
The eye will have a sustained release device of Dexamethasone 0.4 mg placed in the inferior nasal lacrimal system.
Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
The eye will be randomized to receive topical treatment with prednisolone acetate 1% on a tapering dose schedule
Lead Sponsor
Collaborators (1)
Ocular Therapeutix, Inc.
INDUSTRY
Duke University
OTHER